Abstract
Imatinib mesylate is a potent, selective inhibitor of the tyrosine kinase activity of bcr-abl,which is now established as the state-of-the-art treatment for chronic, accelerated or even blastic phase of Philadelphia-positive [Ph(1)(+)] chronic myelogenous leukemia. It is also active in Ph(1)(+) acute lymphoblastic leukemia, but its role in Ph(1)(+) acute myeloid leukemia (AML) is less well investigated. We report here a patient with chemoresistant Ph(1)(+) AML, who responded promptly to one cycle of Ida-FLAG second-line chemotherapy by achieving complete morphologic, immunophenotypic, and cytogenetic remission but not a molecular one. The addition of imatinib mesylate led to a molecular remission, which is sustained for 10 months so far.
MeSH terms
-
Adult
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Benzamides
-
Cytarabine / administration & dosage
-
Female
-
Filgrastim
-
Granulocyte Colony-Stimulating Factor / administration & dosage
-
Humans
-
Idarubicin / administration & dosage
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Piperazines / therapeutic use*
-
Pyrimidines / therapeutic use*
-
Recombinant Proteins
-
Salvage Therapy
-
Treatment Outcome
-
Vidarabine / administration & dosage
-
Vidarabine / analogs & derivatives*
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Recombinant Proteins
-
Cytarabine
-
Granulocyte Colony-Stimulating Factor
-
Imatinib Mesylate
-
Vidarabine
-
Filgrastim
-
Idarubicin